Clinical Trial: Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07756359) titled 'Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)' on Aug. 04.

Brief Summary: The goal of this clinical trial is to learn if Tirzepatide (Zepbound) can decrease bowel frequency in patients that have an ileal-pouch anal anastomosis (IPAA or pouch) better than standard of care anti-diarrheal therapy.

The main question it aims to answer is:

Does Tirzepatide reduce bowel frequency better than standard of care anti-diarrheal therapy in patients that have a pouch

Participants will:

Visit the clinic 5 times, answer questions about symptoms daily, be assigned to take the study product as ...